SURVIVAL rateBONE metastasisBONE diseasesOVERALL survivalCANCER patientsIn this study, we planned to investigate the clinical course of patients with breast cancer with oligometastatic bone disease (OMBD). The patients were grouped according to the characteristics and the sites of metastases. Group I ...
Pamidronate is a second-generation bisphosphonate used in the treatment of tumor-induced hypercalcemia and in the management of bone metastases from breast cancer, myeloma, or prostate cancer. The pharmacokinetics of pamidronate is unknown in cancer patients. To determine the influence of the rate of...
Breast cancer frequently metastasizes to the skeleton. It is estimated that 85% of individuals with advanced disease harbor bone metastases [1]. While ductal carcinoma in situ detected early is 98% curable, bone metastases are basically incurable [2]. Metastatic cancer cells tend to colonize the...
The 5-year survival rate for localized breast cancer is 99%, but decreases to 80% once cells have reached the lymph nodes, and drops to 29% once metastases have formed in distant organs[1]. Triple-negative breast cancer (TNBC), which represents 10–15% of all breast cancers, is known ...
Purpose It is well known that bone metastases from breast cancer usually show osteolytic changes. We retrospectively analysed the computed tomography (CT) appearance of bone metastases to quantify the distribution of lytic, mixed and sclerotic changes in a series of patients presenting with neoplastic...
Winnipeg, MB, Canada and 19National Cancer Action Team, Department of Health, London, UK Background: We investigate whether differences in breast cancer survival in six high-income countries can be explained by differences in stage at diagnosis using routine data from population-based cancer registri...
Survival analysis showed that the signature could distinguish the bone metastasis risks of cancer patients in the test data set and independent data set. Besides, we used the signature genes to construct a centroid classifier. The results showed that our method is effective and performed better ...
Boag's explanation for the lognormal survival time distribution was that if the patient was not cured by treatment, the length of the remaining survival time would be dependent principally on the growth rate of the tumor remnants. Pearlman [37] estimated the growth rates of breast cancer that ...
Such initiatives are expected to encourage the diagnosed breast cancer patients to opt for optimal breast cancer therapeutics, further driving the survival rate of breast cancer therapeutics. Geographically, North America leads the market, supported by advanced healthcare systems, extensive research funding...
of hormone therapy, targeted therapy, chemotherapy or a combination of these is usually the preferred treatment approach for late-stage metastatic breast cancer. However, the 5-year survival rate of women diagnosed with distant metastasis is 27% (https://www.cancer.org/cancer/breast-cancer)....